The best possible security of supply for cancer therapy with CAR-T cells

Federal Joint Committee (G-BA)

17 September 2020 - Medical facilities that treat patients with novel cell therapies (CAR-T cells) must meet newly defined quality requirements. The compulsory professional competence and infrastructure to be provided are intended to ensure high-quality treatment and aftercare that is as free of complications as possible. 

Because the use of CAR-T cells is a medically very innovative, but also risky cancer therapy that can trigger acute serious side effects. 

On Thursday in Berlin, the Federal Joint Committee (G-BA) finally discussed the requirements that apply specifically to the treatment of B-cell neoplasms - malignant diseases of the lymphatic system.

Read G-BA press release [German]

Michael Wonder

Posted by:

Michael Wonder